	版本号/发布时间			:
		第八十六条	用于药品生产或检验的设备和仪器,应当有使用日志,记录内容包括使用、清洁、维护和维修情况以及 <mark>日期、时间</mark> 、所生产及检验的药品名称、规格和批号等。	
	中国-《药品生产质量管理规范》 2010年修订	第一百七十五条	批生产记录的内容应当包括: (二)生产以及中间工序开始、结束的 <mark>日期和时间</mark>	10
,	FILLE COLORS	第一百八十条	批包装记录的内容包括: (二)包装操作日期和时间	955
	中国-《药品生产质量管理规范》	Neu .		
	附录: 计算机化系统 2015年	NA	NA NA	
	中国-《药品记录与数据管理要求	第二十一条	采用电子记录的计算机(化)系统至少应当满足以下功能要求: (一)保证记录时间与系统时间的真实性、准确性和一致性	
	(试行)》 2020年	第二十四条	マース	t
	- 1	- 1	与复核方法的要求。 电子批记录的生产部分至少要包含以下内容:	+
		5.4.2	b) 生产以及中间工序开启、结束的日 <mark>期和时间</mark> 的电子数据 电子批包装记录至少要包含以下内容:	
		5.4.5	b) 包装操作的 <mark>日期和时间</mark> 的电子数据	
	中国-《疫苗生产检验电子化记录 技术指南 (试行)》	8.1.3	针对自动数据采集的获取方式,应当遵循以下要求: c)需确保准确、实时记录数据并能显示正确的时间 <mark>载</mark> 。可采用时钟同步功能,接收国家标准时间。	
	2022年	11.1.5	日期数据项类型: YYYYMMDD, 符合 GB/T 7408 日期、时间数据项类型: YYYYMMDDThhmmss, 符合 GB/T 7408	
		11.2	需记录 <mark>日期及时间</mark> 的数据项:清洁时间、灭菌时间、入库时间、出库时间、取样时间、投料时间、退库时间、生产开始时间、生产结束时间、工序开始时间、工序结束时间、包装操作的时间、取样时间、样品接收时间、样品检验时间、剩余样品处置时间、试剂及标准品的入库时间、领用时间、归还时间、操作时间、销毁时间、审计追踪的操作时	
			间、电子签名时间、细胞制备步骤时间、 Persons who use closed systems to create, modify, maintain, or transmit electronic records shall employ procedures and controls designed to ensure the authenticity, integrity,	+
	504.04.050.044.51	0.44.40	and, when appropriate, the confidentiality of electronic records, and to ensure that the signer cannot readily repudiate the signed record as not genuine. Such procedures and	
	FDA-21 CFR Part 11 Electronic Records; Electronic Signatures	§ 11.10	controls shall include the following: (e) Use of secure, computer-generated, time-stamped audit trails to independently record the date and time of operator entries and actions that create, modify, or delete electronic	
2	Records; Electronic Signatures 2023 年	280	records. Signed electronic records shall contain information associated with the signing that clearly indicates all of the following:	No.
		§ 11.50	(2) The date and time when the signature was executed b. What is "metadata"?	1
	FDA D		Metadata is the contextual information required to understand data. A data value is by itself meaningless without additional information about the data. Metadata is often described	
	FDA-Data Integrity and Compliance With CGMP Q&A	NA	as data about data. Metadata is structured information that describes, explains, or otherwise makes it easier to retrieve, use, or manage data. For example, the number "23" is meaningless without metadata, such as an indication of the unit "mg." Among other things, metadata for a particular piece of data could include a date/time stamp documenting	
	2018年		when the data were acquired, a user ID of the person who conducted the test or analysis that generated the data, the instrument ID used to acquire the data, material status data, the material identification number, and audit trails. Data should be maintained throughout the record's retention period with all associated metadata required to reconstruct the	
	EU-GMP Annex 11 Computerised		CGMP activity (e.g., §§ 211.188 and 211.194). The relationships between data and their metadata should be preserved in a secure and traceable manner.	+
	Systems 2011 年	12.4	Management systems for data and for documents should be designed to record the identity of operators entering, changing, confirming or deleting data including date and time.	1
	EU-GMP Annex 11 Concept Paper on the Revision of Annex 11	NA	- 11 NA - 11 N	1
	2022年 EMA-Data Integrity Q&A	A CONTRACTOR OF THE PARTY OF TH		-
	2016 年	NA NA	NA NA	1
	K		Timestamp Accurate and unambiguous date and time information given in coordinated universal time (UTC) or time and time zone (set by an external standard) should be automatically	
	EMA-Guideline on Computerised	5.5	captured. Users should not be able to modify the date, time and time zone on the device used for data entry, when this information is captured by the computerised system and used as a	
	Systems and Electronic Data in Clinical Trials		timestamp. System design	+
	Clinical Trials 2023 年	lie	One of the advantages of using an ePRO system is that the timestamps of data entry are recorded. The timestamp should record the time of the data entry and not only the time	
5		A5.1.1.1	of the data submission/transmission. Logical checks should be in place to prevent unreasonable data changes such as 'time travel' e.g. going back (months, years in time) or forward into the future based on the	
9	MARIE TO SOLVE COM	A COMPANY	protocol design. Systems and processes should be designed in a way that facilitates compliance with the principles of data integrity. Enablers of the desired behaviour include but are not limited	
8	MHRA-GXP Data Integrity Guidance and Definitions	5.1	to:	
	2018 年	J.1	• At the point of use, having access to appropriately controlled/synchronised clocks for recording timed events to ensure reconstruction and traceability, knowing and specifying the time zone where this data is used across multiple sites.	
1	ICH-E6(R3)《药物临床试验质量管理规范(草案)》	3.16.2	统计编程和数据分析 (e) 申办者应保留与试验结果报告中包含或使用的数据结果相关的统计编程记录,包括所执行的质量控制/验证活动。输出应可追溯到统计软件程序,并应注明日期和时间 载 。	t
	2023 年	J.1U.Z	(e) 中办者应保留与试验给果报告中包含或使用的数据给果相关的统计编程记求,包括所执行的质量控制/验证活动。输出应引追溯到统计软件程序,并应注明日期和时间截,并防止任何更改。	1
	ISPE-GAMP5 第二版 A Risk- Based Approach to Compliant	43.4.2	An ISMS (as defined by ISO 27001 [44]) should be established to define the policies, procedures, and tools to be followed to protect computerized systems data and records. Such policies and procedures include:	
	GxP Computerized Systems 2022 年	43.4.2	policies and procedures include: • Control and synchronization of system clocks	
	Les longitudes	wite jill	Records (paper and electronic) should be kept in a manner that ensures compliance with the principles of this guideline. These include but are not limited to:	1
	AL FILE	4.15	ensuring time accuracy of the system generating the record, accurately configuring and verifying time zone and time synchronisation, and restricting the ability to change dates, time zones and times for recording events;	
	WHO-TRS 1033 Annex 4	(1)	■ ensuring the proximity of an official GxP time source to site of GxP activity and record creation. Example 7: Contemporaneous	+
- 1	Guideline on Data Integrity		Personnel should record data and information at the time these are generated and acquired. For example, when a sample is weighed or prepared, the weight of the sample (date,	
	2021年	Appendix 1	time, name of the person, balance identification number) should be recorded at that time and not before or at a later stage. In the case of electronic data, these should be automatically date- and time-stamped. In case hybrid systems are to be used, including the use for an interim period, the potential and criticality of system breaches should be	н
			covered in the assessment with documented mitigating controls in place. (The replacement of hybrid systems should be a priority with a documented CAPA plan.) Example 11: Accuracy	
		4	when the activity is time-critical, printed records should display the date and time stamp. The major risks associated with data integrity in the data governance of laboratory hybrid systems should be monitored by quality personnel on a regular basis and include, but	-
		6.2.1	are not limited to, the following:	
3	TESE III	ere illi	• Lack of controls to retain source electronic data and data that is "complete" and includes all metadata, which may be due to access to the computer clock, recycle bin, and data files in operating system files	
(S)	FILE OF THE FILE	6.2.2	Results output. The results from hybrid systems (pH meters, balances, and titrators) should be printed with date-and- time stamp, raw data, metadata, measurement values, sample identity, batch	1
	ATTEC.	V.L.2	number, file names, and calculated values.	-
		6.3	Suggested controls to prevent and detect possible data integrity breaches include: Protocol that restricts users from changing the system date and time	1
		6.3.3	Qualification of laboratory instruments and any features or functionality that may compromise data should be verified, for example: • Date and time stamp function should be enabled either in the instrument or on the computer attached to the instrument, but analysts should not have the option of modifying	
			the date and time stamp functionality The following problems, listed with the respective ALCS components, are often encountered and commonly found in audits or cited in FDA Warning Letters:	1
	PDA-No.80 Data Integrity Management System for		• Computers	
	Pharmaceutical Laboratories 2018 年	6.3.11	✓ Time synchronization across all equipment and computers in the laboratory;	
	2018年		✓ Altering or setting back the computer's clock or date and time of the chromatographic injection. • Data Handling	١
	inco me			П
	g	Wer	✓ Data manipulations, such as changing integration, date and time, or method parameters Leberatory data management enfluers their life in the control of t	1
1		6.5	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp	
		6.5	Laboratory data management software typically is validated using the following steps (not necessarily in this order):	- 1
		6.5 7.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution	
			Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk.	
	my car		Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust	
		7.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence	
		7.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: - Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include:	
		7.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation	
		7.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times)	
	PIC/S 041-1-Good Practices for	7.2 8.4 5.5.4	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting exp	
	Data Management and Integrity	7.2 8.4 5.5.4	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting expe	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting exp	
	Data Management and Integrity in Regulated GMP/GDP	7.2 8.4 5.5.4 8.6.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) • Ensure that all key entries are signed & dated, particularly if steps occur over time, i.e. not just signed at the end of the page and/or process.	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. • Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting ex	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Insure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: - Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence - Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: - Outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) - Expectation - Records should be signed and dated using a unique identifier that is attributable to the author. - Potential risk of not meeting	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Insure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. • Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting ex	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Insure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and werification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit programs equipments. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit programs equipments. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. • Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider induse. • Outcomes of a comparison between	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 9.1.5.2	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp. Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (POS), including an effective site audit program, supersyon and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. • Outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times). • Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting expectations/items to be checked • Ensure that all key entries are signed & dated, particularly if step	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: • Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • Outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting expectations/items to be checked • Ensure that all key entries are s	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessments the results of the investigation and comprehensive assessments the results of the investigation and comprehensive assessments the prevent recurrence. • Assurance that incidents of missing data, delection of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. • Assurance that incidents of missing data, delection of complexity. Factors to consider include: • Outcomes of a companison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times). • Expectation • Final Particular of the production of the production of the page and/or process. Some very simple electronic systems, e.g. balances, pH meters or simple processing equipment which do not store data, generate directly-printed paper records. These types of systems an	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): Ensure PDFs of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP biolaminescence platform) system and actification is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider indude: • uncomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation Records should be signed and dated by an analysis of the page and/or process. Some very simple electronic systems explained and page and page and/or process. Some very simple electron	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): Ensure PDFs of any converted data files are not ediable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioluminescence platform) system adult trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include. • Uncomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times). 4. Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting expectations/items to be checked. • Insure that all key entries are signed & dated, particularly if steps occur over time, i.e. not just signed at the end of the page and/o	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): • Insure PDFs of any converted data files are not editable and bear a date- and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and reserved in the reserved produce and electronic record that is retrievable and reserved in the supplementation of the view of advanced methods with a validated data recrelitatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation in the use of advanced methods with a validated data recrelitation in the supplementation of the view of the documentation system. Will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Arry permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. **Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. **Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider include: • outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) **A Expectation Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk for not meeting expectations/items to be checked • Fissure that alike yentries are signed & dated, particularly if	
	Data Management and Integrity in Regulated GMP/GDP Environments	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): - Ensure PDF of any converted data files are not editable and bear a date-and-time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stamped photography equipment. This can include automation and the use of datwaced methods with a validated data recording (for example, ATP bioluminescence platform) system and audit train a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence: - Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. - Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider induce. - autocomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times). - Records should be signed and dated using a unique identifier that is attributable to the author. - Potential risk of not meeting expectations/firems to be checked. -	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): - Insure PISO for any converted data files are not exident data files are not exident data files are not exident data files are not exidenced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally time-and-date-stampaed photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP biodiuminescence platform) system and automation is a validable, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following seps are commonly taken to prevent recurrence: - Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence - Risk assessments should focus on a business process (e.g. production, QC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (IT) system functionality or complexity. Factors to consider includie: - outcomes of a comparison between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) 4. Expectation - Records should be signed and dated using a unique identifier that is attributable to the author. Potential risk of not meeting expectations/items to be checked - Ensure that all key entries are signed & dated, particu	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): Fersure PDF of any convented data files are not editable and hear a data—and time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate reades or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitably sines—and—date—stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bicluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce a land integrity and a weak PQS increases the data integrity risk, of the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting roct cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. *Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. *Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. *Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. *Assurance that incidents of missing data, deletion of data, and changes to time-and-data flow and the methods of generating and processing data from the data flow of the prevent of the data flow and the prevent of the da	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): Finsure PDF of any convented date flies are not establishe and bear a data—and—ima stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relatively tamper-proof or digitally sinne-and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data ecording (for example, ATP bicluminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceurical quality system (1925), including an effective site audit program, supervisory and Quality Unit presence in the isboratory, and a robust periodic review of the documentation system. Will reduce data integrity risk, of the other hand, a weak PCS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. *Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. *Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. *Assurance that incidents of missing data, deletion of data, and changes to time-and-data flows and the methods of generating and processing data. *Assurance that incidents of missing data, deletion of data, and changes to time-and-data flows and the methods of generating and processing data deletions are provided to a comparison because the processing data of the action of the strength of the data data flows and the pro	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): Firsure PDFs of any convented data files are not editable and bear a data—and—time stamp Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and relabively tamper—proof or digitally time—and—date—stamped probapsity equipment. This can inducide automation and the use of advanced methods with a validated data recording for example. APP bioiuminescence platform) system and audit ratal capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a week PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. * Assurance that incidents of missing data, deletion of data, and changes to time—and—date stamps has stopped and actions have been taken to prevent recurrence. * Assurance that incidents of missing data, deletion of data, and changes to time—and—date stamps has stopped and actions have been taken to prevent recurrence. * Assurance that incidents of missing data, deletion of data, and namually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition time). * Assurance that incidents of missing data, deletion of state, and namually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times). * Assurance that incidents of missing that the prevention of th	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software spotally is validated using the following steps froot necessarily in this corder): Finsure PDFs of any converted data file are not editable and bear a data-of-line stamp. Risk factors for the collection, control, and verification of microbiology data are reduced with computer interface sechnology, such as automated plate readers or rapid methods are controlled to the control of the collection, control, and verification of microbiology data are reduced with computer interface sechnology, such as automated plate readers or rapid methods are of advanced methods with a validated data recording (for example, ATP bioduminescence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (PQS), including an effective site audit program, supervisory and Quality Unit presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. Cn the other hand, a vesik PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly laken to prevent recurrence: * Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been state to prevent recurrence. * Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been state to prevent recurrence. * Assurance that incidents of missing data, deletion of data, and changes to time-and-date stamps has stopped and actions have been state to prevent recurrence. * Assurance that incidents of missing data, deletion of data, and changes to the state stamps have stopped and actions and prevent recurrence. * Assurance that incidents of missing data, deletion of data, and changes to the state stamps have s	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): Feature PDF of any convented data lites are not editable on betar a data-and-intensity of the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce are described record or digitally time—and-date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bindiminescence platform) system and audit trait capabilities. Even when a technological solution is not available, a strong pharmaceutical quality setter (present deplication) and the use of advanced methods with a validated data recording (for example, ATP bindiminescence platform) system and audit trait capabilities. Even when a technological solution is not available, a strong pharmaceutical quality setter (present in the biboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the necessary of the control of the page of the policy of the page of the policy of the page of th	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this norder): - Ensure PDFs of any converted data like are not existed and bara a data—and—time stamp - Risk factors for the collection, corror, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods as that produce an electronic record that is retrievable and releasibly symper—proof of digitally time—and-date—stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioduminescence platform) system and audit trail presence in the laboratory, and a robust periodic review of the documentation system, will reduce data integrity risk. Any permanent brain data stronge simplemented blood the based upon the results of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. - Assurance that incident of infesting data, deletion of data, and changes to time- and- date stamps has stopped and actions have been taken to prevent recurrence. - Assurance that incident of insign glata, deletion of data, and datages to time- and- date stamps has stopped and actions have been taken to prevent recurrence. - Risk assessments should focus on a business process (e.g. production, O.C), evaluate data flows and the methods of generating and processing data, and not just consider information technology (ff) system functionality or complexity, factors to consider indused. - Lincard that active the companion between electronic system data and manually recorded events (e.g. apparent discrepancies between analytical reports and raw-data acquisition times) - Expectation - Expectat	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): FourwerPDF of any convented data files are not editable and beta a data-and immessarily. Resk feators for the collection, control, and verification of microbiology data are reduced with computer interface technology, such as automated plate readers or rapid methods that produce an electronic record that is redivable and redevelop tamper-pool of digitally time. and—date-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP biodiuminecance platform) system and sudit trail capabilities. Even when a technological solution is not available, a storing pharmacentical quality bysem for exemption of digitally time. The companies will be seen to the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the excess the data integrity risk. Any permanent changes implemented should be based upon the results of the excess the data integrity risk. Any permanent changes implemented and the data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Assurance that incredients of missing data, and changes to immediate the stamps has stopped and actions have been taken to prevent recurrence. **Assurance that incredients of missing data, and not prevent recurrence. **Legistation** **Assurance that incredients of missing charges in the control of the page and/or process. **Resk sessements should be supred and dated using a unique identifier that is attributable to the author. **Posternal incredients provided initiated poperuturity to influence the presentation of data by the process of page and/or process. **Ensure that all key entries are signed & steed, particularly if steps occur over time, i.e. not, just signed at the end of the page and/or process. **Domi	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software spically is solidated using the following steps (not messarely in this carder): Feature PDFs of any commend data file are not established and are a data—and messarely Risk factors for the collection, cortrol, and wrification of microbiology data are reduced with computer instruction control, and wrification of microbiology data are reduced with computer instruction control, and wrification of microbiology data are reduced with computer instruction control, and wrification of microbiology data are reduced with computer instruction of control of the computer instruction of th	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is validated using the following steps (not necessarily in this order): Formare PDFs of any convented data first ae in not establish and bear a dise-and intensity. Rek factors for the collection, control, and verification of microbiology, data are reduced with computer intensities technology, such as automated plate readers or rapid methods that produce are deterrance record that is entervated and retworking or digitally stems and date stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP biodiminiscence platform) system and audit trail capabilities. Even when a technological solution is not available, a strong pharmaceutical quality system (50), including an effective size audit programs, supervisory and Quality (10) previewer in the biodistory, and a robust periodic review of the documentation system, will reduce data integrity risk. On the other hand, a weak PQS increases the data integrity risk. Any permanent changes implemented should be based upon the results of the merispation and comprehensive assessment. the resulting port cause determination, and the operation of the comprehensive assessment in the program of the comprehensive assessment. The results of the comprehensive assessment should focus on a business process (e.g. production, CC), evaluate data flows and the methods of generating and processing data, and not just consider information technology (17) system functionally or completely. Scators to consider information technology (17) system functionally or completely. Scators to consider information technology (17) system functionally or completely. Scators to consider information technology (17) system functionally or exceptions). Scators are simple processes and the comprehensive assessment should be assisted and case and an animally recorded events (e.g. apparent discrepancies between enalytical reports and raw-data acquisition times). 4. Expectation Records	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity 2022 年	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software spirally is validated using the following steps (not messally in this cortex). Frame PDFs of any connected data file are not editable and sear a data and more starpy. Fish datases for the collection, correct, and verification of microbiology data are reduced with computer interface behalogy, such as automated plate readers or rapid methods that produce an electronic record that is retrievable and reducely tamper-poor of cigally time—and -data-starped photography equipment. This can include automation and the use of advanced methods with a validated data recording for earnphs. ATP bioliuminescence platformly system and suddit tall capabilities. Even when a technological solution is not available, a storing pharmaceutical quality system. (PSC), including an effective size audit program, supervisory and capability their presence in the resolution produces are controlled to the computer of the commentation system will reduce data incoginy risk. On the other hand, a weak PQS increases the data inceptly risk. Assumance that includes on a business process (e.g. production), CQC evaluate data flows and the methods of generating and processing data, and rot put consider selection of the commentation system will be considered to the commentation and	
	Data Management and Integrity in Regulated GMP/GDP Environments 2021 年 APIC-Practical Risk-Based Guide for Managing Data Integrity	7.2 8.4 5.5.4 8.6.1 8.9.1 9.1.5.2 9.5 9.8 4.1	Laboratory data management software typically is solidated using the following steps (not meessarely in this cortex). Finale PSRs dataces for the collection, control, and verification of microbiology data are reduced with computer inertaine exhencing, such as automated place readers or rapid methods that produce an electronic record that is retrievable and reflacively tamper-poor of cigally sine—and dise-stamped photography equipment. This can include automation and the use of advanced methods with a validated data recording (for example, ATP bioliumnessense platform) system and audit trail capabilities. Even when a technicological solution is not evaletible, a storing pharmaceutical quality system (2005), including an effective size audit program, supervisory and robusts periodic review of the documentation system, will reduce data integrity risk. Any permanent changes implemented about be based upon the essales of the investigation and comprehensive assessment, the resulting root cause determination, and the gap analysis. The following steps are commonly taken to prevent recurrence. Assurance than indicests of missing data, deletion of stata, and changes to time-and-date stamps has stopped and actions have been taken to prevent recurrence. Raks assessments should focus on a business process (e.g. production, CQL evaluate data flows and the methods of generating and grocessing data, and not just consider information technology (f) hystem incrincolary) complexely. Factors to consider include. • unaccomment of a comparison between electronic systems and changes to the author. February of the state of the state of the supplement of the page and/or process. **Energy that a state of the record and the supplement which do not store data, generate directly-printed paper records. These types of exercise desired of state data state and the state of the control of the supplement which do not store data, generate directly-printed paper records. These types of carries and the state of the page and or process. **Se	